Potentiation of LSD-induced stimulus control by fluoxetine in the rat

Life Sciences

Volumn 59, Issue 18, 1996, Pages

  Fiorella, David ^a   Helsley, Scott ^a   Rabin, Richard A ^a   Winter, J C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

(+) fluoxetine; ( ) fluoxetine; 5 HT(1A) receptors; 5 HT2 receptors; drug induced stimulus control; hallucinogen; LSD; selective serotonin reuptake inhibitor

Indexed keywords

FLUOXETINE; LYSERGIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG POTENTIATION; ENANTIOMER; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT;

ANIMALIA;

EID: 16044371912     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00490-0     Document Type: Article

References (25)

1. 1. L.D. JOHNSTON, P.M. O'MALLEY and J.G. BACHMAN, National Survey Results on Drug Use from The Monitoring The Future Study, 1975-1992 (vol 1: secondary school students; vol II college students). Rockville, MD NIDA (1993).
2. 2. J.C. COYNE, S. FECHNER-BATES and T.L. SCHWENK, Gen. Hosp. Psychiatry 16 267-276 (1994).
3. 3. H. MARKEL, A. LEC, R.D. HOLMES and E.F. DOMINO, J. Pediatrics 125 817-819 (1994).
4. nd edn. 672-673, American Psychiatric Press, Washington, (1995).
5. 5. L. GRAM, New Eng. J. Med. 331 1354-1361 (1994).
6. 6. D.T. WONG, P.P. BYMASTER, L.R. REID, R.W. FULLER and K.W. PERRY, Drug Dev. Res. 6 397-403 (1985).
7. 7. R.A. GLENNON, NIDA monograph #146, GC Lin and RA Glennon (Eds), 4-32, USPGO, Washington D.C. (1994).
8. 8. J.C. WINTER, NIDA monograph #146, GC Lin and RA Glennon (Eds), 157-182, USPGO, Washington D.C. (1994).
9. 9. D.M. KUHN, F.J. WHITE and J.B. APPEL, Neuropharmacology 17 257-263 (1978).
10. 10. J.C. WINTER, Contemporary Research in Behavioral Pharmacology, D. Blackman and, J. Sanger (Eds), 209-238, Plenum Press, New York, (1978).
11. 11. K.P. KEENAN, P.F. SMITH and K.A. SOPER, Pathobiology of the ageing rat. Volume 2, In: V. Mohr, D.L. Dungworth and C.C. Capen (Eds), 609-628, Washington, DC, (1994).
12. 12. D. FIORELLA, R.A. RABIN and J.C. WINTER, Psychopharmacology 119 222-230 (1995a).
13. 13. D. FIORELLA, R.A. RABIN and J.C. WINTER, Psychopharmacology 121 347-356 (1995b).
14. 14. S. HJORTH and S.B. AUERBACH, Eur. J. Pharmacol. 260 251-255 (1994).
15. 15. D. VERGE', G. DAVAL, M. MARCHINKIEWICZ, A. PATEY, S. EL MESTIKAWY, H. GOZLAN and M. HAMON, J. Neuroscience 6 3474-3482 (1986).
16. 16. G.K. AGHAJANIAN, W.E. FOOTE and M.H. SHEARD, Science 161 706-708 (1968).
17. 17. F.D. YOCCA, A.S. EISON, D.K. HYSLOP, E. RYAN, D.P. TAYLOR and G. GIANUTSOS, Life Sci. 49 1777-1785 (1991).
18. 18. J.C.P. HEATON and S.L. HANDLEY, Br. J. Pharmacol. 98 687P(1989).
19. 19. H.H.G. BERENDSEN and C.L.E. BROEKKAMP, Eur. J. Pharmacol. 253 83-89 (1994).
20. 20. K.R. BONSON, J.W. BUCKHOLTZ and D.L. MURPHY, Neuropsychopharmacol. 14 425-436 (1996).
21. 21. J.F. STOLZ, C.A. MARSDEN and D.N. MIDDLEMISS, Psychopharmacology 80 150-155 (1983).
22. 22. D.R. NELSON, D.R. THOMAS and A.M. JOHNSTON Acta. Psychiatr. Scand. 80 21-23 (1989).
23. 23. A.S. EISON, M.S. EISON, F.D. YOCCA and G. GIANUTSOS, Life Sci. 44 1419-1427 (1989).
24. 24. E.F. MARSHALL, J. MILNE and S.M. DODDS, Neuroreport 3: 1009-1012 (1992).
25. 25. C. DE MONTIGNY, Y. CHAPUT and P. BLIER, J. Clin. Psychiatry 51 4-8 (1990).